Skip to main content

Novo Holdings A/S's Form 4 filing

IO Biotech, Inc. (IOBT) · filed Aug 11, 2023

Accession no.
0001209191-23-045444
Filed
Aug 11, 2023
Trade date
Aug 9, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $5.01M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Novo Holdings A/SCIK 000138832510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2023Common StockPPurchaseAcquired+2,469,135$2.03F1+$5,012,344.055,707,467Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2023Common StockPPurchaseAcquired+2,469,135$2.03F1+$5,012,344.052,469,135Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)